ImageneBio - Proyeksi bathi mangsa ngarep IMA
The development of ImageneBio Inc (IMA) relies on progressing through clinical trial stages, while its existing liquidity reserve remains sufficient. Business success is based on the uniqueness of early trial results and rigorous patent protection. The company's projected profit levels demonstrate the potential to establish premium drug pricing, where the current status is 0.00, confirming the actual dynamics of operational expansion.
Rincian analitis lan laporan data perusahaan Ikena Oncology (IMA)
- kuotasi lan prakiraan analis:
- rincian nilai pasar emiten:
- indikator kapitalisasi buku:
- data utang lan likuiditas:
Rasio Total Utang marang Ekuitas ImageneBio Inc|IMA - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas ImageneBio|IMA - Utang agregat perusahaan|Utang-utang marang kapitalisasi buku Ikena Oncology|IMA - Utang jangka dawa|Utang jangka cendhak perusahaan Ikena Oncology|Likuiditas cepet ikenaoncology.com
- data bathi resik lan rasio valuasi:
IMA - Penghasilan resik|Proyeksi bathi mangsa ngarep ImageneBio Inc|IMA - Pangali P/E|Pangali Forward P/E ImageneBio|IMA - Rasio rega marang wutah bathi resik|Pangali EV/EBITDA Ikena Oncology|IMA - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Ikena Oncology|IMA - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan ikenaoncology.com|IMA - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep ImageneBio Inc
- indikator volume dodolan lan pendapatan:
Analisis umum perusahaan:ImageneBio Inc, IMA
This indicator reflects the market's dynamic mathematical expectations regarding the issuer's future earnings in real time. By analyzing the expected profit growth, the investor assesses the consensus valuation of the business considering current market conditions. For ImageneBio Inc (IMA), such calculations are based on the potential of future patent monopolies in immunotherapy. The stability of the line confirms market confidence in long-term demand from medical institutions. This captures the asset's resilience ahead of clinical approvals.
Pesaing ImageneBio Inc
Bathi mangsa ngarep ARGX|BNTX: Penghasilan resik sing dikarepake|Proyeksi bathi mangsa ngarep ABVX|Prakiraan bathi perusahaan ADMA Biologics Inc|Bathi sing dikarepake Protagonist Therapeutics Inc PTGX|IMVT - Bathi mangsa ngarep|KNSA - Bathi sing dikarepake|grifols.com (GRFS) - Bathi mangsa ngarep|ADPT (Adaptive Biotechnologies Corporation) - Bathi mangsa ngarep|Celldex Therapeutics Inc (CLDX) - Proyeksi bathi mangsa ngarep|Bathi sing dikarepake Aurinia Pharma|Prakiraan bathi resik BCRX (BioCryst Corp)|Proyeksi bathi mangsa ngarep VERA|DNTH - Bathi resik sing dikarepake|Proyeksi bathi mangsa ngarep PHVS (Pharvaris)|Prakiraan bathi perusahaan AbCellera Corp (ABCL)|TRML - Bathi sing dikarepake|Precigen Corp (PGEN) - Bathi mangsa ngarep|PHAR: Proyeksi bathi mangsa ngarep|nektar.com (NKTR) - Proyeksi bathi mangsa ngarep|UPB (Upstream Bio) - Proyeksi bathi mangsa ngarep|ZBIO - Proyeksi bathi resik|Proyeksi bathi mangsa ngarep IMNM|GOSS - Bathi resik sing dikarepake|Bathi sing dikarepake KalVista Pharmaceuticals KALV|SEPN: Prakiraan bathi resik|Pieris Pharmaceuticals, Inc. - Proyeksi bathi mangsa ngarep|Bathi resik sing dikarepake Savara Inc|RIGL: Proyeksi bathi mangsa ngarep|ANAB (AnaptysBio Inc.) - Bathi sing dikarepake|ATXS (Astria Therapeutics) - Proyeksi bathi mangsa ngarep|engene.com (ENGN) - Prakiraan bathi perusahaan|Bathi sing dikarepake RAPT Therapeutics (RAPT)|JBIO - Bathi resik sing dikarepake|Aclaris - Bathi mangsa ngarep|Penghasilan resik sing dikarepake KYTX|Tiziana Life Sciences - Proyeksi bathi mangsa ngarep|Prakiraan bathi perusahaan cabalettabio.com CABA|Ventyx Biosciences, Inc. (VTYX) - Bathi sing dikarepake|Prakiraan bathi resik THTX|AVTX (Avalo Therapeutics Inc.) - Proyeksi bathi mangsa ngarep|Bathi mangsa ngarep Eledon Pharmaceuticals, Inc (ELDN)|Proyeksi bathi mangsa ngarep AGEN|Prakiraan bathi perusahaan climbbio.com|Bathi sing dikarepake Zura Bio ZURA|ATYR - Bathi mangsa ngarep|Adagene Corp - Proyeksi bathi mangsa ngarep|STTK - Proyeksi bathi mangsa ngarep|equilliumbio.com (EQ) - Bathi sing dikarepake|Bathi forward CNTB (Connect Biopharma Holdings Limited)|IMUX (Immunic Therapeutics) - Proyeksi bathi mangsa ngarep|ATRA: Penghasilan resik sing dikarepake|Proyeksi bathi mangsa ngarep IFRX|Proyeksi bathi mangsa ngarep X4 Pharmaceuticals, Inc (XFOR)|Bathi sing dikarepake Adicet Bio, Inc. ACET|Penghasilan resik sing dikarepake CELU|INMB - Bathi sing dikarepake|Barinthus Biotherapeutics PLC (BRNS) - Bathi mangsa ngarep|KZR: Proyeksi bathi mangsa ngarep|SAB Biotherapeutics Inc (SABS) - Proyeksi bathi mangsa ngarep|Bathi mangsa ngarep AKTX|ENLV: Penghasilan resik sing dikarepake|Proyeksi bathi mangsa ngarep QTTB|Prakiraan bathi perusahaan GeoVax Labs|Bathi sing dikarepake Edesa EDSA|IBIO - Bathi mangsa ngarep|CARM - Bathi sing dikarepake|xtlbio.com (XTLB) - Bathi mangsa ngarep|BOLT (boltbio.com) - Bathi mangsa ngarep|HCW Biologics (HCWB) - Proyeksi bathi mangsa ngarep|Bathi sing dikarepake Aptevo Therapeutics, Inc.|Prakiraan bathi resik AIM (aimimmuno.com)|Proyeksi bathi mangsa ngarep ADTX|GRI - Bathi resik sing dikarepake|Proyeksi bathi mangsa ngarep XRTX (XORTX Therapeutics)|Prakiraan bathi perusahaan Vyome Holdings Inc. (HIND)|REVB - Bathi sing dikarepake|Indaptus Corp (INDP) - Bathi mangsa ngarep|SCNI: Proyeksi bathi mangsa ngarep|CalciMedica (CALI) - Proyeksi bathi mangsa ngarep|AFMD (Affimed NV) - Proyeksi bathi mangsa ngarep|ALLK - Proyeksi bathi resik|Proyeksi bathi mangsa ngarep HOOK|IGMS - Bathi resik sing dikarepake|Bathi sing dikarepake iTeos Therapeutics ITOS|OCEA: Prakiraan bathi resik|TC BioPharm - Proyeksi bathi mangsa ngarep|Bathi resik sing dikarepake Third Harmonic Bio Inc.
